Easing of cancer drug import norms by China set to benefit Indian pharma firms

摘要

New norms for drug imports announced by the Chinese government are expected to benefit Indian pharma companies in the oncology segment. "From December, China will be allowing cancer patients to import drugs which are not registered with Chinese regulators," informed Mr. R. Uday Bhaskar, Director, Pharmaceutical Exports Promotion Council (Pharma-excil).